Fusion Antibodies plc (AIM: FAB) has secured a new antibody engineering contract worth more than £45,000 with an established European-listed global pharmaceutical customer, marking a further commercial win for its
Avacta to present AVA6207 at Barcelona cancer conference
Avacta Therapeutics (AIM: AVCT) has announced plans to present its next-generation dual-payload cancer drug candidate AVA6207 at the 2026 EORTC-NCI-AACR Symposium in Barcelona, highlighting a new approach designed to overcome
MedPal AI revenue reaches £4.1m as repeat orders double
MedPal AI plc (AIM: MPAL; FRA: Z1N) has reported strong October trading, with group revenue climbing to approximately £4.1 million as its New Health weight management business recorded a sharp
Peptide capacity race: how GLP-1 is reshaping supply
The peptide capacity race: how GLP-1 demand is reshaping the supply chain from factory floor to lab bench
Avacta reports 11.4-month progression-free survival with AVA6000 in salivary gland cancer trial
Avacta Therapeutics (AIM: AVCT) has reported encouraging clinical results from its ongoing Phase 1a/1b trial of faridoxorubicin (AVA6000), with median progression-free survival reaching 11.4 months in a selected group of
Avacta reports promising AVA6103 cancer trial progress with tumour responses in Enhertu-resistant models
Avacta Therapeutics (AIM: AVCT) has reported encouraging preclinical results for its experimental cancer treatment AVA6103, demonstrating tumour responses in models resistant to Enhertu, as the company advances its Phase 1
Connected Care and the Ageing Market: A Primer
Demographics rarely make a dramatic headline, yet they shape whole sectors for decades. Every pension uprating story is, underneath, a story about how many people are living longer. Investors who
Fusion Antibodies lands contract with major US drugmaker
Fusion Antibodies plc (AIM: FAB) has secured a new contract worth more than £85,000 with an existing US pharmaceutical client, strengthening its commercial relationship with a major industry customer and
ValiRx highlights 5.55% Ambrose Healthcare stake following €161 million AM-Pharma acquisition
ValiRx Plc (AIM: VAL) has highlighted its indirect 5.55% shareholding in Ambrose Healthcare following the private pharmaceutical company’s agreement to acquire AM-Pharma for up to €161 million, drawing investor attention
Physiomics secures £102,000 drug development contract as new awards surpass £970,000
Physiomics plc (AIM: PYC) has secured a new £102,000 drug development modelling contract, taking the total value of contract awards announced since May 2026 to more than £970,000, exceeding the
UK welfare spending tops £320bn as disability benefit claims surge to seven million
Britain’s welfare system is facing renewed scrutiny after an investigation revealed that approximately seven million people now receive sickness or disability benefits, raising concerns over the long-term sustainability of public
MedPal AI reports 42,500 customers as Mounjaro business grows
MedPal AI plc (AIM: MPAL) has announced that its New Health business has become one of the UK’s top 30 Mounjaro providers by supply volume, climbing from 3,048th to 29th